A 12‐gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5‐fluorouracil or FOLFIRI

Currently, there is no marker in use in the clinical management of colon cancer to predict which patients will respond efficiently to 5‐fluorouracil (5‐FU), a common component of all cytotoxic therapies. Our aim was to develop and validate a multigene signature associated with clinical outcome from...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Pathol Clin Res
Prif Awduron: Paquet, Eric R., Cui, Jing, Davidson, David, Pietrosemoli, Natalia, Hassan, Houssein Hajj, Tsofack, Serges P., Maltais, Annie, Hallett, Michael T., Delorenzi, Mauro, Batist, Gerald, Aloyz, Raquel, Lebel, Michel
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2015
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4939880/
https://ncbi.nlm.nih.gov/pubmed/27499901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cjp2.17
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg